Kill Switch, page-3

I have referred to a study by researchers from Memorial Sloan Kettering into the use of Omomyc as a kill switch. The report itself which was published in September 2014 is titled a Cell Engineering Strategy to Enhance the Safety of Stem Cell Therapies. Highlights from the paper include the finding that cancer and normal tissues derived from iPSCs differentially depend upon Myc and that engineering iPSCs with a dominant negative Myc allele such as Omomyc is a therapeutic fail-safe strategy.

Is the research still relevant or has it since been discarded for any number of a host of reasons?

I can't find any follow-up research but suspect that the report findings are relevant to the future of iMYC applications. The iMYC program appears to have the potential to complement a number of other approaches in the ultimate drive towards a cure for cancer. Combinations already canvassed include iMYC in combination with;

1. checkpoint inhibitors - PD-L1 pathway.
2. MDM2 drugs - MDM2-p53 pathway.
3. pro death peptides - BH3-mimetric drugs: Bcl-2, Mcl-1.
4. CAR-T

These are four of the biggest areas in oncology today. There are solid pointers that Phylogica is advancing towards a meaningful Myc inhibitor to bring into the clinic. The appointment of its two new non-executives champion this opinion. If its true, expect a new round of collaborations in 2017-18 which will feature some of the leading global players in oncology including immuno-oncology.